Zacks Investment Research Lowers Alphatec (ATEC) to Sell
Zacks Investment Research lowered shares of Alphatec (NASDAQ:ATEC) from a hold rating to a sell rating in a research note released on Friday morning.
According to Zacks, “Alphatec Holdings, Inc. is a medical technology company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders. The Company’s principal product offering includes a variety of spinal implant products and systems consisted of components, such as spine screws and rods, spinal spacers, plates, and various biologics offerings. Alphatec Holdings, Inc. is headquartered in Carlsbad, California. “
ATEC has been the subject of a number of other reports. HC Wainwright set a $4.00 price target on shares of Alphatec and gave the stock a buy rating in a research note on Tuesday, February 26th. ValuEngine raised shares of Alphatec from a sell rating to a hold rating in a report on Wednesday, January 2nd.
Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Thursday, March 7th. The medical technology company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). Alphatec had a negative return on equity of 85.82% and a negative net margin of 31.60%. The company had revenue of $25.34 million during the quarter. Equities research analysts anticipate that Alphatec will post -0.45 EPS for the current fiscal year.
In other Alphatec news, Director Evan Bakst acquired 20,566 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were bought at an average price of $2.59 per share, with a total value of $53,265.94. Following the completion of the acquisition, the director now owns 726,912 shares in the company, valued at approximately $1,882,702.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kelli Mari Howell acquired 100,000 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was acquired at an average cost of $2.59 per share, for a total transaction of $259,000.00. The disclosure for this purchase can be found here. Company insiders own 44.40% of the company’s stock.
A number of large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP lifted its holdings in Alphatec by 8.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 95,662 shares of the medical technology company’s stock valued at $219,000 after purchasing an additional 7,705 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in Alphatec by 49.2% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 29,063 shares of the medical technology company’s stock valued at $67,000 after purchasing an additional 9,579 shares in the last quarter. Beacon Pointe Wealth Advisors LLC purchased a new position in Alphatec during the fourth quarter valued at approximately $36,000. Royce & Associates LP lifted its holdings in Alphatec by 124.8% during the fourth quarter. Royce & Associates LP now owns 35,000 shares of the medical technology company’s stock valued at $80,000 after purchasing an additional 19,432 shares in the last quarter. Finally, Suntrust Banks Inc. purchased a new position in Alphatec during the fourth quarter valued at approximately $58,000. 18.57% of the stock is currently owned by institutional investors and hedge funds.
Alphatec Company Profile
Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.
Recommended Story: How the Consumer Price Index (CPI) is calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.